2,452 results match your criteria: "Institut Jules Bordet-Université libre de Bruxelles[Affiliation]"
Diagn Pathol
January 2025
Laboratoire Hospitalier Universitaire de Bruxelles - Universitair Laboratorium Brussel, Université Libre de Bruxelles LHUB-ULB, Brussels, Belgium.
Background: Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less common. These two diseases may share mutations and/or cytogenetic anomalies, which can lead to malignant proliferations.
View Article and Find Full Text PDFLeuk Res Rep
December 2024
Internal Medicine Department, Institut Jules Bordet - Hôpital Universitaire de Bruxelles (H.U.B.), Université Libre de Bruxelles (ULB), Brussels, Belgium.
We describe the case of a female patient with May-Hegglin syndrome who developed peripheral T-cell lymphoma not otherwise specified. The patient presents with systemic lupus erythematous phenotype and myelofibrosis secondary to T-cell lymphoma. Peripheral T-cell lymphoma not otherwise specified, represents 25 % of all peripheral T-cell lymphoma.
View Article and Find Full Text PDFNat Commun
January 2025
Bioinformatics and computational systems biology of cancer, Institut Curie, Inserm U900, PSL Research University, Paris, France.
Immunotherapy is improving the survival of patients with metastatic non-small cell lung cancer (NSCLC), yet reliable biomarkers are needed to identify responders prospectively and optimize patient care. In this study, we explore the benefits of multimodal approaches to predict immunotherapy outcome using multiple machine learning algorithms and integration strategies. We analyze baseline multimodal data from a cohort of 317 metastatic NSCLC patients treated with first-line immunotherapy, including positron emission tomography images, digitized pathological slides, bulk transcriptomic profiles, and clinical information.
View Article and Find Full Text PDFCells
December 2024
Radiotherapy Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.
Definitive chemoradiotherapy (CRT) is a cornerstone of treatment for locoregionally advanced head and neck cancer (HNC). Research is ongoing on how to improve the tumor response to treatment and limit normal tissue toxicity. A major limitation in that regard is the growing occurrence of intrinsic or acquired treatment resistance in advanced cases.
View Article and Find Full Text PDFBMC Cancer
January 2025
Laboratoire d'Oncologie et de Chirurgie Expérimentale, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Pract Radiat Oncol
January 2025
Department of Radiation-Oncology, Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium. Electronic address:
Life (Basel)
December 2024
Dermatology Unit, Department of Medical, Surgical and Neurosciences, University of Siena, 53100 Siena, Italy.
"Harald Kittler" was not included as an author in the original publication [...
View Article and Find Full Text PDFCancers (Basel)
December 2024
IRIBHM Jacques E. Dumont, Université libre de Bruxelles, 1070 Brussels, Belgium.
Background: The diagnosis of malignant thyroid nodules is mainly based on the fine-needle aspiration biopsy (FNAB). To improve the detection of malignant nodules, different molecular tests have been developed. We present a new molecular signature based on altered miRNA expressions and specific mutations.
View Article and Find Full Text PDFESMO Open
January 2025
Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
Background: Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy of anticancer agents. In the phase III PALLAS trial, the addition of palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use of PPIs affected survival outcomes in patients treated with palbociclib in PALLAS.
View Article and Find Full Text PDFBJUI Compass
December 2024
Department of Urology, Jules Bordet Institute, Hôpital Universitaire de Bruxelles Université Libre de Bruxelles Brussels Belgium.
Objective: The aim of this study was to assess the precision and safety of targeted microwave ablation (TMA) using organ-based tracking (OBT) fusion, in patients with intermediate risk prostate cancer.
Patients And Method: We conducted a prospective, multicentric trial. Eligible patients had a prostate-specific antigen (PSA) < 20 ng/mL, a magnetic resonance imaging (MRI)-visible index tumour of Gleason score 3 + 4, with largest axis ≤15 mm and distant of at least 5 mm from the rectum and apex.
Radiography (Lond)
December 2024
Université Libre de Bruxelles (ULB), Brussels University Hospital, Jules Bordet Institute, Radiotherapy Department, Rue Meylemeersch 90, 1070 Bruxelles, Belgium.
Introduction: Radiation Therapists (RTTs) are crucial in delivering Radiotherapy (RT) to cancer patients. The advancements in RT technology and the increasing cancer incidence have heightened the demand for RTTs, necessitating strategic workforce planning at the national level. This study aims to identify and estimate current and future RTT workforce in Belgium.
View Article and Find Full Text PDFInt J Cancer
December 2024
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) is a dNTP hydrolase important for intracellular dNTP homeostasis and serves as tumor suppressor and modulator of antimetabolite efficacy in cancer, though largely unexplored in breast cancer (BC). A cohort of patients with early BC (n = 564) with available gene expression data (GEP) was used. SAMHD1 protein expression was assessed by immunohistochemistry performed on tissue microarrays.
View Article and Find Full Text PDFCurr Oncol
December 2024
Department of Digestive Surgery and Digestive Surgical Oncology, Jules Bordet Institute, The Brussels University Hospital (H.U.B), Université Libre de Bruxelles (ULB), Meylemeersch Street 90, 1070 Brussels, Belgium.
Ovarian cancer (OC) is diagnosed at a locally advanced stage in two-thirds of cases. The first line of treatment consists of cytoreductive surgery (CRS) combined with neoadjuvant and/or adjuvant chemotherapy. However, CRS can be associated with high rates of postoperative complications (POCs), and detection of fragile patients at high risk of POCs is important.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
January 2025
Groupe d'Imagerie Cutanée Non Invasive (GICNI) of the Société Française de Dermatologie (SFD), Paris, France.
Ann Oncol
December 2024
Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC, USA; Division of Hematology-Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address:
Background: In HER2+ early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) biology and prognostic implications across 4 neoadjuvant studies of trastuzumab with or without lapatinib, and with or without chemotherapy: CALGB 40601, PAMELA, NeoALTTO and NSABP B-41.
Patients And Methods: We compared tumor and immune gene expression changes during neoadjuvant treatment and their association with with event-free survival (EFS) by uni- and multivariable Cox regression models in different cohorts and timepoints: 452 RD samples at baseline including 169 with a paired RD, and biomarker changes during neoadjuvant therapy, evaluating model performance via the c-index.
Results: Analysis of 169 paired tumor samples revealed a shift in intrinsic subtype proportions from HER2-Enriched at baseline (50.
Oncoimmunology
December 2025
Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer.
View Article and Find Full Text PDFEur J Cancer
January 2025
Department of Radiation Oncology, Ghent University Hospital/Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Clin Exp Dermatol
December 2024
Department of Dermatology, Hôpital Erasme - Hôpitaux universitaires de Bruxelles (HUB), Brussels, Belgium.
FEBS Open Bio
December 2024
CNRS, LISM, IMM FR3479, Aix Marseille Univ, France.
In the search for new antituberculosis drugs with novel mechanisms of action, we evaluated the antimycobacterial activity of a panel of eight phenolic acids against four pathogenic mycobacterial model species, including Mycobacterium tuberculosis. We demonstrated that salicylic acid (SA), as well as the iodinated derivatives 5-iodo-salicylic acid (5ISA) and 3,5-diiodo-salicylic acid (3,5diISA), displayed promising antitubercular activities. Remarkably, using a genetically encoded mycobacterial intrabacterial pH reporter, we describe for the first time that SA, 5ISA, 3,5diISA, and the anti-inflammatory drug aspirin (ASP) act by disrupting the intrabacterial pH homeostasis of M.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
December 2024
Department of Dermatology, Hôpital Erasme, HUB, Université Libre de Bruxelles, Brussels, Belgium.
Introduction: Line-field confocal optical coherence tomography (LC-OCT) represents one of the newest non-invasive in vivo skin imaging techniques. Previous studies described morphologic criteria of basal cell carcinoma (BCC) under LC-OCT examination. Preliminary data on LC-OCT diagnostic performance for BCC have recently been published but showed only a modest improvement compared to dermoscopy, possibly due to study limitations.
View Article and Find Full Text PDFClin Case Rep
December 2024
Department of Stomatology, Oral & Maxillofacial Surgery CHU Saint Pierre Brussels Belgium.
This case report contributes to understanding the complexities of ameloblastoma recurrence despite meeting recommended guidelines and highlights the importance of long-term follow-up and tailored surgical approaches.
View Article and Find Full Text PDFNat Commun
November 2024
Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
In HER2-positive breast cancer, clinical outcome and sensitivity to HER2-targeted therapies are influenced by both tumor and microenvironment features. However, we are currently unable to depict the molecular heterogeneity of this disease with sufficient granularity. Here, by performing gene expression profiling in HER2-positive breast cancers from patients receiving adjuvant trastuzumab in the ALTTO clinical trial (NCT00490139), we identify and characterize five molecular subtypes associated with the risk of distant recurrence: immune-enriched, proliferative/metabolic-enriched, mesenchymal/stroma-enriched, luminal, and ERBB2-dependent.
View Article and Find Full Text PDFCancer Treat Rev
January 2025
Department of Medicine I, Division of Oncology, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. Electronic address:
Nat Commun
November 2024
Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Brussels, Belgium.
While triple-negative breast cancer (TNBC) is known to be heterogeneous at the genomic and transcriptomic levels, spatial information on tumor organization and cell composition is still lacking. Here, we investigate TNBC tumor architecture including its microenvironment using spatial transcriptomics on a series of 92 patients. We perform an in-depth characterization of tumor and stroma organization and composition using an integrative approach combining histomorphological and spatial transcriptomics.
View Article and Find Full Text PDFJCO Oncol Pract
November 2024
Luca Arecco, MD, Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Academic Trials Promoting Team, Brussels, Belgium; Abeid Omar, MD, Department of Clinical Oncology, Kenyatta University Teaching, Referral and Research Hospital (KUTRRH), Nairobi, Kenya; Luciana de Moura Leite, MD, Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil; Kristina Janković, MD, Clinic of Oncology, University Clinical Center Nis, Nis, Serbia; Gabriella Gentile, MD, Department of Radiological, Oncological and Pathological Sciences, Sapienza-University of Rome, Rome, Italy; Mihaela Stana, MD, Department of Medical Oncology, Elysée Hospital, Alba Iulia, Romania; Hatem A. Azim Jr, MD, PhD, Cairo Cure Oncology Center, Cairo, Egypt; and Matteo Lambertini, MD, PhD, Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy, Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.